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H-Ras, N-Ras, and K-Ras proteins have distinct biological properties, despite ubiquitous expression and similar affinities for 
regulators and effectors. C-terminal hypervariable regions that distinguish H-Ras, N-Ras, and K-Ras proteins direct them to 
distinct membrane compartments, where they may encounter regulators and effectors at different local concentrations. Jura 
and coworkers now report that these membrane-targeting domains direct differential ubiquitination of Ras proteins and so 
provide a molecular mechanism to explain the sorting process and, perhaps, some of the dramatic differences in biological 
potency among H-Ras, N-Ras, and K-Ras proteins.Biological differences between members 
of the Ras family (K-Ras, N-Ras, and 
H-Ras) have been recognized for many 
years but have not been understood fully 
at the molecular level. Ras proteins play 
distinct roles in human cancer despite 
sharing the same regulators and effec-
tors and despite similar patterns of gene 
expression. K-Ras is activated frequently 
in cancers of the lung, colon, pancreas, 
endometrium, and biliary tract, whereas 
activating mutations in N-Ras or H-Ras 
are rare in these diseases. On the other 
hand, H-Ras is frequently mutated in 
tumors derived from salivary glands, but 
N-Ras and K-Ras are not (http://www.
sanger.ac.uk/genetics/CGP/). Activated 
alleles of N-Ras can lead to metastatic 
melanoma, whereas activated H-Ras is 
associated with Spitz nevi that do not 
progress to malignant disease (Bastian et 
al., 2000). Germline activating mutations 
in H-Ras cause Costello syndrome, a 
developmental disease that is associated 
with increased incidence of cancer (Aoki 
et al., 2005), whereas germline mutations 
in K-Ras can cause Noonan’s syndrome 
(Schubbert et al., 2006). Analysis of Ras 
gene function in mice has revealed that K-
Ras is an essential gene, but H-Ras and 
N-Ras are not, even when knocked out in 
combination (reviewed in Malumbres and 
Barbacid, 2002).
How can we account for these strik-
ing biological differences? All three Ras 
proteins are farnesylated, but they have 
different secondary membrane localiza-
tion signals. N-Ras is acylated with one 
palmitoyl group and H-Ras with two. On 
the other hand, K-Ras4B, the most com-
mon splice variant, contains a polyba-
sic stretch of amino acids (the K-Ras4A 
splice variant contains a single palmitoyl 
group like N-Ras). These different modi-
fications are largely responsible for their 
localization in different plasma membrane 
microdomains, as well as different endo-
membrane compartments. For example, 
a constitutive depalmitoylation/repalmi-cancer cell April 2006 toylation cycle is responsible for the con-
tinuous shuttling of H- and N-Ras proteins 
between the plasma membrane and Golgi 
complex (Rocks et al., 2005). K-Ras, pre-
viously thought to reside exclusively at the 
plasma membrane, has now been shown 
to relocalize to other endomembrane 
compartments, including endoplasmic 
reticulum, Golgi, and mitochondria, by a 
mechanism dependent on phosphoryla-
tion within the polybasic domain (Bivona 
et al., 2006). These dramatic spatial 
separations seem capable of explaining 
many of the biological differences noted 
above, since Ras regulators and effectors 
are themselves likely to be differentially 
localized. A new Molecular Cell paper by 
Jura et al. takes another major step toward 
explaining exactly how spatial sorting is 
regulated: they show that H-Ras and N-
Ras, but not K-Ras4B, can be subject to 
ubiquitination (Jura et al., 2006), and that 
this differential modification plays a key 
role in compartmentalization and thus sig-
nal transduction.
Ubiquitination, the covalent attach-
ment of ubiquitin to lysine residues of 
target proteins, has been implicated in 
the regulation of a wide variety of cellular 
functions. Ubiquitin, a highly conserved 
protein of 8 kDa, has several lysine resi-
dues itself, and ubiquitin molecules can 
form different types of chains by a pro-
cess known as polyubiquitination. Lysine 
48-linked polyubiquitin chains target sub-
strates for proteosomal degradation. Other 
types of ubiquitin conjugates such as 
monoubiquitin or lysine 63-linked chains 
regulate other functions independently 
of proteolytic degradation (Haglund and 
Dikic, 2005). Among these, ubiquitination 
is well known to act as a regulatory signal 
directing internalization and sorting in the 
endocytic compartment of many mem-
brane proteins (Hicke and Dunn, 2003).
Ubiquitination of H-Ras stabilizes its 
association with endosomes and modu-
lates H-Ras’ ability to activate the MAPK 
pathway. H-Ras ubiquitination was not affected by EGF treatment or by its acti-
vation state but still may be subject to 
regulatory mechanisms. The hypervari-
able region of H-Ras (the last 25 amino 
acids) is sufficient to dictate ubiquitina-
tion but does not seem to be the site of 
modification. A different lysine residue in 
the remaining portion of the H-Ras pro-
tein must be the acceptor site for ubiquitin. 
Both farnesylation and palmitoylation are 
necessary for ubiquitination. Jura et al. 
suggest that it is the subsequent localiza-
tion at specific membrane microdomains 
that determines H- and N-Ras ubiqui-
tination. It is also possible, however, that 
the hypervariable region may physically 
interact with a targeting component of the 
ubiquitin ligase complex.
An H-Ras mutant that can no longer 
be ubiquitinated is 4-fold more potent than 
wild-type at activating Erk, and this cor-
relates with H-Ras’ increased ability to 
recruit Raf-1 to the membrane fraction. 
Conversely, an H-Ras protein fused at its 
N terminus to an ubiquitin moiety prefer-
entially localizes to early endosomes and 
is less efficient at recruiting Raf-1 and 
activating Erk. Thus, H-Ras ubiquitina-
tion and the resulting association with the 
endocytic compartment appears to impair 
H-Ras’ ability to activate the MAPK path-
way. This would be consistent with the 
known role of endocytosis in signal termi-
nation by removal of activated receptors 
from the plasma membrane. However, it 
is now clear that endocytic compartments 
are sites of active signaling and that endo-
cytosis can play a crucial role in signal 
propagation and amplification and in the 
spatiotemporal regulation of signaling 
pathways (Miaczynska et al., 2004).
It will be interesting to determine the 
ability of ubiquitinated Ras to regulate 
other Ras effector pathways. It is plau-
sible that, whereas endosomal-localized 
Ras may be impaired in its ability to inter-
act with Raf, it could preferentially inter-
act with other of Ras’ many effectors and 
selectively activate other pathways. Even 243
	 p r e v i e w sresults on the MAPK pathway should be 
interpreted with caution. This study does 
not rule out the possibility of localized Erk 
activation in the endosomal compartment 
having specific substrates and functions. It 
is intriguing that at least two MAPK path-
way scaffolds, β-arrestin and MP1, are 
known to localize in endosomes (Kolch, 
2005). SEF, a Golgi-localized scaffold, 
suggests a molecular mechanism for the 
differential spatial regulation of the MAPK 
pathway: SEF binding to Mek and Erk 
inhibits Erk translocation to the nucleus 
and allows signaling to cytosolic sub-
strates but not nuclear substrates (Torii 
et al., 2004). It is possible that the vari-
ous Ras isoforms will recruit Raf kinases 
(and other effectors) to different mem-
brane subcompartments under different 
circumstances. This, in combination with 
the role of compartment-specific scaf-
folds, may result in Erk signaling output 
being channeled to different substrates 
and different functions.
A better understanding of the mecha-
nisms regulating the segregation of the 
various Ras isoforms into different mem-
brane compartments and how that is 
coupled to their signaling and biological 244 properties in different cell types, may offer 
clues to their still unexplained mutational 
spectrum. Furthermore, as illustrated 
by the work of Bivona et al., it may also 
suggest new approaches for therapeutic 
intervention (Bivona et al., 2006). Despite 
the disappointing results of farnesyltrans-
ferase inhibitors as anti-Ras cancer drugs, 
modifications regulating other steps in 
their membrane localization process may 
offer new targets for isoform-specific, anti-
Ras therapies.
pablo rodriguez-Viciana1 and 
Frank McCormick1,*
1University of California, San Francisco, 
Comprehensive Cancer Center, 2340 
Sutter Street, San Francisco, California 
94115 
*E-mail: mccormick@cc.ucsf.edu
Selected reading
Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., 
Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., 
Suzuki, Y., Kure, S., and Matsubara, Y. (2005). Nat. 
Genet. 37, 1038–1040.
Bastian, B.C., LeBoit, P.E., and Pinkel, D. (2000). Am. J. Pathol. 157, 967–972.
Bivona, T.G., Quatela, S.E., Bodemann, B.O., 
Ahearn, I.M., Soskis, M.J., Mor, A., Miura, J., 
Wiener, H.H., Wright, L., Saba, S.G., et al. (2006). 
Mol. Cell 21, 481–493.
Haglund, K., and Dikic, I. (2005). EMBO J. 24, 
3353–3359.
Hicke, L., and Dunn, R. (2003). Annu. Rev. Cell 
Dev. Biol. 19, 141–172.
Jura, N., Scotto-Lavino, E., Sobczyk, A., and Bar-
Sagi, D. (2006). Mol. Cell 21, 679–687.
Kolch, W. (2005). Nat. Rev. Mol. Cell Biol. 6, 827–
837.
Malumbres, M., and Barbacid, M. (2002). Nat. Rev. 
Cancer 3, 7–13.
Miaczynska, M., Pelkmans, L., and Zerial, M. 
(2004). Curr. Opin. Cell Biol. 16, 400–406.
Rocks, O., Peyker, A., Kahms, M., Verveer, P.J., 
Koerner, C., Lumbierres, M., Kuhlmann, J., 
Waldmann, H., Wittinghofer, A., and Bastiaens, 
P.I. (2005). Science 307, 1746–1752.
Schubbert, S., Zenker, M., Rowe, S.L., Boll, S., 
Klein, C., Bollag, G., van der Burgt, I., Musante, 
L., Kalscheuer, V., Wehner, L.E., et al. (2006). Nat. 
Genet. 38, 331–336.
Torii, S., Kusakabe, M., Yamamoto, T., Maekawa, 
M., and Nishida, E. (2004). Dev. Cell 7, 33–44.
DOI 10.1016/j.ccr.2006.03.025cancer cell April 2006
